Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer

被引：1
|
作者：
Bartsch, R. [1 ,2 ]
Berghoff, A. [1 ,2 ]
Pluschnig, U. [1 ,2 ]
Bago-Horvath, Z. [3 ]
Dubsky, P. [4 ]
Rottenfusser, A. [5 ]
Gnant, M.
Mader, R. [1 ,2 ,4 ]
Zielinski, C. C. [1 ,2 ]
Steger, G. G. [1 ,2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Ctr Canc, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Dept Radiotherapy, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71503-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [21] Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
    Rupert Bartsch
    Andrea Rottenfusser
    Catharina Wenzel
    Karin Dieckmann
    Ursula Pluschnig
    Gabriela Altorjai
    Margaretha Rudas
    Robert M. Mader
    Richard Poetter
    Christoph C. Zielinski
    Guenther G. Steger
    Journal of Neuro-Oncology, 2007, 85 : 311 - 317
  • [22] Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer
    Ono, Makiko
    Ando, Masashi
    Yunokawa, Mayu
    Nakano, Eriko
    Yonemori, Kan
    Matsumoto, Koji
    Kouno, Tsutomu
    Shimizu, Chikako
    Tamura, Kenji
    Katsumata, Noriyuki
    Fujiwara, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) : 48 - 52
  • [23] Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection
    Morikawa, Aki
    Wang, Rui
    Patil, Sujata
    Diab, Adi
    Yang, Jonathan
    Hudis, Clifford A.
    Mcarthur, Heather L.
    Beal, Kathryn
    Seidman, Andrew D.
    CLINICAL BREAST CANCER, 2018, 18 (05) : 353 - 361
  • [24] Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells
    Scott R. Burks
    Luciana F. Macedo
    Eugene D. Barth
    Katherine H. Tkaczuk
    Stuart S. Martin
    Gerald M. Rosen
    Howard J. Halpern
    Angela M. Brodie
    Joseph P. Y. Kao
    Breast Cancer Research and Treatment, 2010, 124 : 121 - 131
  • [25] IMPACT OF HER2/NEU STATUS ON OVERALL SURVIVAL AND DISTANT BRAIN FAILURE IN PATIENTS WITH BREAST CANCER BRAIN METASTASES
    Dragovic, Aleksandar F.
    Sawrie, Stephen M.
    Meredith, Ruby F.
    Spencer, Sharon A.
    Markert, James M.
    Guthrie, Barton L.
    Fiveash, John
    NEURO-ONCOLOGY, 2009, 11 (05) : 667 - 667
  • [26] Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells
    Burks, Scott R.
    Macedo, Luciana F.
    Barth, Eugene D.
    Tkaczuk, Katherine H.
    Martin, Stuart S.
    Rosen, Gerald M.
    Halpern, Howard J.
    Brodie, Angela M.
    Kao, Joseph P. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) : 121 - 131
  • [27] Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer
    Massard, C.
    Brain, E.
    Dunan, A.
    Mathieu, M.
    Guinebretiere, J.
    Abuin, G. Gomez
    Floiras, J.
    Spielmann, M.
    Delaloge, S.
    Andre, F.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 120
  • [28] The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
    Foged, Niels T.
    Brugmann, Anja
    Jorgensen, Jan T.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (03) : 233 - 242
  • [29] De-escalated radiotherapy for HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes undergoing anti-HER2 targeted therapy
    Liu, Jing
    Huang, Suning
    Bi, Zhuofei
    Zhang, Xiaoxue
    He, Ziqing
    Lan, Xiaowen
    Tan, Yuting
    Lin, Xiao
    Zhou, Wenyi
    Huang, Xiaobo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
12345